First psychedelic healthcare fund launches in Britain
A new fund has launched in Britain that will allow investors to put their money into mind altering drugs to be used for medical purposes. (Getty Images)
Britain’s first investment fund dedicated solely to psychedelic healthcare launched this week, allowing investors to put money into mind altering drugs for medical use.
The fund, launched by London-based venture capital firm Neo Kuma, has an investment thesis focused on clinically proven psychedelic medicines that it believes will hit the market in the next five years.
The launch comes after clinical trials have demonstrated the potential of psychedelic drugs to treat needs in mental illness, including post-traumatic stress disorder, depression, addiction and anxiety.